RNAi / siRNA Deal Benchmarks in Ophthalmology

Median Upfront

$698M

Range: $384M - $998M

Total Deal Value

$3.3B

Range: $2.1B - $4.4B

Royalty Rate

9.9% - 19.9%

Tiered up to 23.9%

Dev Milestones

$518M

Range: $350M - $688M

Model Your Deal

Market Analysis

RNAi / siRNA therapies in ophthalmology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in ophthalmology is $698M, with total deal values reaching $3.3B. Development milestones average $518M, while regulatory milestones contribute $647M.

The ophthalmology rnai / sirna landscape is characterized by moderate competitive intensity concentrated in retinal disease and dry eye. Gene therapies for inherited retinal diseases, extended-duration intravitreal agents, and topical biologics are expanding the opportunity set. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna ophthalmology deals range from 9.9% to 19.9% at the base tier, with tiered escalation reaching 13.9%-23.9% on blockbuster sales. Commercial milestones averaging $1.4B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna ophthalmology licensing deal?

Based on our analysis, Phase 2 rnai / sirna licensing deals in ophthalmology average $698M in upfront payments, with a range of $384M to $998M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for rnai / sirna ophthalmology transactions?

The median total deal value for Phase 2 rnai / sirna assets in ophthalmology is $3.3B, ranging from $2.1B to $4.4B. This includes development milestones ($518M), regulatory milestones ($647M), and commercial milestones ($1.4B).

What royalty rates are standard for rnai / sirna deals in ophthalmology?

Base royalty rates for rnai / sirna ophthalmology transactions range from 9.9% to 19.9%, with tiered escalations reaching 13.9%-23.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in rnai / sirna ophthalmology deals?

RNAi / siRNA ophthalmology deals allocate approximately 79% of total deal value to milestones. Development milestones ($518M) make up the largest share, followed by commercial milestones ($1.4B) and regulatory milestones ($647M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

RNAi / siRNA Deal Benchmarks in Ophthalmology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Ophthalmology

Monoclonal Antibody in Ophthalmology

RNAi / siRNA in Oncology

RNAi / siRNA in Neurology

Ready to Calculate Your Deal Terms?